| Conferences \ BioProcessing, Biologics & Biotherapeutics Congress \ Antibody and Peptide Therapeutics \ Agenda \ Stephen Brocchini |
| Register | Login |
Moving from Biosimilars to Biobetters with PEGylationThursday, 21 July 2011 at 16:30  Add to Calendar ▼2011-07-21 16:30:002011-07-21 17:30:00Europe/LondonMoving from Biosimilars to Biobetters with PEGylationSELECTBIOenquiries@selectbiosciences.comThe biosimilars markets for endogenous cytokines such as interferon alpha-2 and GCSF were eroded by the introduction of their PEGylated variants. PEGylation allows for decreased dosing frequency which can be important for improved patient compliance and efficacy. Continued improvements in PEGylation technologies to achieve better product homogeneity provide opportunities to develop biobetter versions of both PEGylated and non-PEGylated protein based medicines. |
Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonAntibody and Peptide TherapeuticsSELECTBIOenquiries@selectbiosciences.com
